Page last updated: 2024-08-25

almagate and Myocardial Infarction

almagate has been researched along with Myocardial Infarction in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
AbouChehade, JE; Bakri, SJ; Dalvin, LA; Damento, GM; Garcia, M; Hodge, DO; Iezzi, R; Meissner, I; Shah, SM; Starr, MR1
Matthé, E; Sandner, D1
Joussen, AM; Wong, D1

Other Studies

3 other study(ies) available for almagate and Myocardial Infarction

ArticleYear
Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
    JAMA ophthalmology, 2019, 05-01, Volume: 137, Issue:5

    Topics: Aged; Aptamers, Nucleotide; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Male; Minnesota; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Survival Rate; Time Factors; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Wet Macular Degeneration

2019
[Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011, Volume: 108, Issue:4

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Humans; Intravitreal Injections; Male; Myocardial Infarction; Ranibizumab; Retrospective Studies; Risk Factors; Stents; Stroke; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2011
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthal
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2011, Volume: 249, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cause of Death; Hemorrhage; Humans; Macular Degeneration; Myocardial Infarction; Photochemotherapy; Ranibizumab; Risk Factors; Stroke; Vascular Endothelial Growth Factor A

2011